BioCryst Pharmaceuticals | BCRX - Operating Expenses


BioCryst Pharmaceuticals reported $-397.38M in Operating Expenses for its fiscal quarter ending in September of 2026.





Operating Expenses Change Date
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
Chugai Pharma JPY 201.8B 21.07B Sep/2026
Daiichi Sankyo JPY 483.8B 5.85B Sep/2026
DBV Technologies USD 64.8M 16.9M Sep/2026
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Glaxosmithkline GBP 6.76B 1.42B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Novavax USD 126.2M 23.62M Dec/2025
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026